MA35294B1 - Probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of her2 breast cancer treatment - Google Patents
Probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of her2 breast cancer treatmentInfo
- Publication number
- MA35294B1 MA35294B1 MA35508A MA35508A MA35294B1 MA 35294 B1 MA35294 B1 MA 35294B1 MA 35508 A MA35508 A MA 35508A MA 35508 A MA35508 A MA 35508A MA 35294 B1 MA35294 B1 MA 35294B1
- Authority
- MA
- Morocco
- Prior art keywords
- her2
- breast cancer
- primers
- choice
- applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L’invention concerne le domaine du diagnostique du cancer du sein her2. Plus précisément, l’invention divulgue une méthode utilisant de nouveaux sondes et amorces pour détecter le gène her2 en format multiplexe et ses applications dans le choix de traitement du cancer du sein. Le protocole de la méthode utilise la pcr quantitative en temps réel (qpcr) sous un format simplexe ou multiplexe. Les gènes contrôles sélectionnés dans la présente convention (rpl3o, rplp37, et mrpl19) appartiennent à la famille des gènes codants pour des protéines ribosomales et sont décrits ici pour la première fois dans la quantification de her2.The invention relates to the field of the diagnosis of her2 breast cancer. More specifically, the invention discloses a method using novel probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of breast cancer treatment. The protocol of the method uses the real-time quantitative pcr (qpcr) in a simplex or multiplexed format. The control genes selected in this convention (rpl3o, rplp37, and mrpl19) belong to the family of coding genes for ribosomal proteins and are described here for the first time in her2 quantification.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MA35508A MA35294B1 (en) | 2012-12-27 | 2012-12-27 | Probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of her2 breast cancer treatment |
PCT/MA2013/000023 WO2014104867A1 (en) | 2012-12-27 | 2013-08-08 | Probes and primers for detection of the her2 gene and a regulator gene (ribosomal) in multiplex format: use in selecting treatment for her2 breast cancer |
TNP2015000292A TN2015000292A1 (en) | 2012-12-27 | 2015-06-25 | PROBES AND PRIMERS FOR DETECTING THE HER2 GENE AND A MULTIPLEX FORMAT CONTROL (RIBOSOMAL) GENE: APPLICATIONS IN THE CHOICE OF TREATING HER2 BREAST CANCER |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MA35508A MA35294B1 (en) | 2012-12-27 | 2012-12-27 | Probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of her2 breast cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35294B1 true MA35294B1 (en) | 2014-08-01 |
Family
ID=49724642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35508A MA35294B1 (en) | 2012-12-27 | 2012-12-27 | Probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of her2 breast cancer treatment |
Country Status (3)
Country | Link |
---|---|
MA (1) | MA35294B1 (en) |
TN (1) | TN2015000292A1 (en) |
WO (1) | WO2014104867A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA37437B1 (en) * | 2014-10-17 | 2016-12-30 | Mascir (Morrocan Found For Advanced Science Innovation & Research) | Breast cancer diagnostic kit in qpcr multiplex reaction and its application in the evaluation of the status of the her2 protein and the choice of treatment |
MA41742B1 (en) * | 2017-12-29 | 2020-02-28 | Moroccan Foundation For Advanced Science Innovation And Res Mascir | Method for the determination of the positivity threshold of the overexpression of the her2 protein in breast cancer and other cancers. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2574447A1 (en) * | 2004-07-15 | 2006-01-26 | University Of Utah Research Foundation | Housekeeping genes and methods for identifying the same |
-
2012
- 2012-12-27 MA MA35508A patent/MA35294B1/en unknown
-
2013
- 2013-08-08 WO PCT/MA2013/000023 patent/WO2014104867A1/en active Application Filing
-
2015
- 2015-06-25 TN TNP2015000292A patent/TN2015000292A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TN2015000292A1 (en) | 2016-10-03 |
WO2014104867A1 (en) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250245A1 (en) | Spatially distinguished, multiplex nucleic acid analysis of biological specimens | |
EA201891294A1 (en) | THE METHOD OF WHICH A BISPECIFIC PROTEIN COMPLEX IS USED | |
IN2014DN07531A (en) | ||
MX2016016904A (en) | Analysis of nucleic acid sequences. | |
MX2022012384A (en) | Compositions and methods for screening mutations in thyroid cancer. | |
MA40662A1 (en) | Antibodies against tigit | |
MX2017008553A (en) | Multiplex quantitative pcr. | |
AR088514A1 (en) | BISPECIFIC IMMUNOLIGANTS DIRECTED AGAINST TNF | |
FR2963976B1 (en) | IMAGE PROCESSING METHOD FOR DETERMINING SUSPECTED ZONES IN A TISSUE MATRIX, AND ITS USE FOR 3D NAVIGATION THROUGH THE TISSUE MATRIX | |
MA35130B1 (en) | Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri) | |
EA201792080A1 (en) | HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF THEIR APPLICATION | |
MX367192B (en) | Pathogenesis quantification systems and treatment methods for citrus greening blight. | |
EA201692148A1 (en) | HUMANIZED ANTIBODIES AGAINST CEACAM1 | |
FR3044017B1 (en) | TRANSIENT TRANSFECTION METHOD FOR RETROVIRAL PRODUCTION | |
MX2018001697A (en) | Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers. | |
MA35294B1 (en) | Probes and primers for detecting the her2 gene in multiplexed format and its applications in the choice of her2 breast cancer treatment | |
MA37437B1 (en) | Breast cancer diagnostic kit in qpcr multiplex reaction and its application in the evaluation of the status of the her2 protein and the choice of treatment | |
EA201290107A1 (en) | METHOD FOR DETERMINING A PATIENT AS A SUSTAINABLE OR NOT SUSTAINABLE FOR IMMUNOTHERAPY | |
WO2016005905A3 (en) | Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages | |
MX338076B (en) | Quantitative, highly multiplexed detection of nucleic acids. | |
SG11201811032RA (en) | A method for target protein identification using thermal stability shift-based fluorescence difference in two-dimensional gel electrophoresis | |
EP3415505A3 (en) | Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (mtc) | |
MA36330B1 (en) | Kit for the diagnosis of chronic myeloide leukemia in multiplex reaction and its applications in the monitoring of treatment and residual disease | |
EA201490201A1 (en) | DETECTION OF THE PRAME GENE EXPRESSION IN CANCER DISEASES | |
JP6346493B2 (en) | Method for predicting the effect of peptide vaccine therapy |